Mcm Polimedica 2 Sp. z o.o.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
Researchers at Mcm Polimedica 2 are studying Chronic Heart Failure With Reduced Ejection Fraction to determine whether a new oral agent can lower the risk of cardiovascular death and heart‑failure hospitalization.
- Heart failure outcome measures
- Risk reduction strategies
- Innovative oral therapies
The trial involves a multidisciplinary team of 11 investigators and aims to improve long‑term survival for patients with severe cardiac dysfunction.
Respiratory Tract Diseases
A study focusing on Chronic Obstructive Pulmonary Disease (COPD) evaluates the impact of benralizumab on reducing frequent exacerbations in patients with high peripheral blood eosinophils.
- Exacerbation frequency reduction
- Eosinophil‑guided treatment
- Management of severe COPD
Conducted at the Warsaw clinic, this research seeks to provide a targeted biologic option for individuals with a history of severe COPD attacks.
Skin and Connective Tissue Diseases
The site is evaluating povorcitinib in adults with Chronic Spontaneous Urticaria to assess its ability to control persistent hives and improve patient quality of life.
- Urticaria symptom control
- JAK inhibitor efficacy
- Quality‑of‑life outcomes
This trial adds to the limited therapeutic options for chronic hives and involves collaboration among dermatology specialists at the facility.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 28 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 6 by active trials.
- 1Merck Sharp & Dohme LLC1active
lock +5 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Mcm Polimedica 2 Sp. z o.o.
lock Showing 1 of 13 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimilar (DRL_Tocilizumab) with tocilizumab reference product (RoActemra®) administered by the subcutaneous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritis | Dr Reddy's Laboratories Limited | Phase III | Not Yet Recruiting | — | — |
IMP list
lock Showing 1 of 28 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Placebo | 2 | Unknown | 2026-04-13 | 2026-04-13 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.